Compare Heron Therapeutics Inc (HRTX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs KeyCorp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while KeyCorp trades at $20.13 (market cap $21.45B). The key difference: KeyCorp is far larger — about 315.4× Heron Therapeutics Inc's market cap, and KeyCorp pays a 4.08% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and KeyCorp for 66 Days on average.
| HRTX | KEY | |
|---|---|---|
Market Cap | $68.01M | $21.45B |
Volume | 1,891,941 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $1.49 | $23.99 |
52-Week Low | $0.27 | $16.78 |
Typical Hold Time | 35 Days | 66 Days |
Enterprise Value | $174.75M | $34.63B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
KeyCorp (KEY) trades at $19.83, down 1.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank has beaten EPS estimates for three consecutive quarters, with a Q3 2026 estimate of $0.4615. Revenue rebounded to $7.29B in 2025, and the net income margin improved to 26.72%. Recent corporate actions include a $0.21 dividend and key executive appointments in wealth and retail banking.
The outlook is cautiously optimistic, supported by strong analyst consensus (60.79% buy rating) and a $25.00 price target implying 26% upside. Investment opportunities include earnings momentum and shareholder returns via dividends and buybacks. Risks involve interest rate sensitivity, competitive pressures on margins, and macroeconomic uncertainty affecting loan growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
